MERCK KGAA STARTS TH-302 PHASE III STUDY ON PANCREAS CANCER(ENG)

     (The following press release from Merck KGaA was received by e-mail. It 
was not confirmed by the sender.) 
News Release 
Your Contact
Phyllis Carter
+49 6151 72-7144 
Merck Initiates TH-302 Phase III MAESTRO Study in Patients With Locally
Advanced or Metastatic Pancreatic Adenocarcinoma 
• Pivotal Phase III study with investigational hypoxia-targeted drug aims
to
 enroll 660 patients 
Darmstadt, Germany, January 25, 2013 – Merck today announced the initiation
of the global Phase III MAESTRO study, assessing the efficacy and safety of
investigational hypoxia-targeted drug TH-302 in combination with
gemcitabine in patients with previously untreated, locally advanced
unresectable or metastatic pancreatic adenocarcinoma. The study is being
carried out pursuant to a global licensing and co-development agreement for
TH-302 between Merck and Threshold Pharmaceuticals Inc., which includes an
option for Threshold to co-commercialize in the U.S. MAESTRO stands for
TH-302 in the treatment of MetastAtic or unrESectable pancreaTic
adenocaRcinOma. 
The complete news release can be downloaded at the following link:
http://news.merck.de/N/0/C129EE9000B3AE31C1257AFE002AF6CC/$File/MaestroEng.pdf 
Merck's news releases are available at this address:
http://media.merck.de
You may change your subscription at any time by following this link:
http://subscribe.merck.de
Unsubscribe this service with:
http://news.merck.de/N/WEBOK?OpenForm&WA=2&FN=3&ID=2F7B430E0746A994C125782300588
64F 
________________________________________________________________________________
____________ 
Merck KGaA
External Communications
E-mail: Media.Relations@merck.de
Hotline: +49 (0) 6151/72-5000 
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient,
you must not copy this message or attachment or disclose the contents to
any other person. If you have received this transmission in error, please
notify the sender immediately and delete the message and any attachment
from your system. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not accept liability for any omissions or errors in this
message which may arise as a result of E-Mail-transmission or for damages
resulting from any unauthorized changes of the content of this message and
any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not guarantee that this message is free of viruses and does
not accept liability for any damages caused by any virus transmitted
therewith. 
Click http://disclaimer.merck.de to access the German, French, Spanish and
Portuguese versions of this disclaimer.